Table 3.
Summary of multivariate Cox proportional hazard regression analysis of independent prognostic factors for locoregionally advanced nasopharyngeal carcinoma in high-risk cluster.
| Endpoint | Characteristic | HR (95% CI) | p |
|---|---|---|---|
| PFS | |||
| T classification (T4 versus T3) | 1.375 (1.047–1.806) | 0.022 | |
| LDH (⩾245 versus <245 U/l) | 1.323 (1.064–1.645) | 0.012 | |
| ALB (⩾40 versus <40 g/l) | 0.664 (0.531–0.829) | <0.001 | |
| Treatment modality | <0.001 | ||
| (IMRT alone versus CCRT) | 1.672 (1.077–2.593) | 0.022 | |
| (NACT+IMRT alone versus CCRT) | 1.040 (0.778–1.390) | 0.792 | |
| (NACT+CCRT versus CCRT) | 0.690 (0.561–0.849) | <0.001 | |
| (CCRT+ACT versus CCRT) | 0.967 (0.660–1.417) | 0.862 | |
| OS | |||
| Age (⩾45 versus <45, years) | 1.257 (1.017–1.553) | 0.034 | |
| N classification (N3 versus N2) | 1.301 (1.060–1.597) | 0.012 | |
| LDH (⩾245 versus <245 U/l) | 1.404 (1.088–1.812) | 0.009 | |
| ALB (⩾40 versus <40 g/l) | 0.727 (0.553–0.957) | 0.023 | |
| Treatment modality | <0.001 | ||
| (IMRT alone versus CCRT) | 1.827 (1.134–2.945) | 0.013 | |
| (NACT+IMRT alone versus CCRT) | 1.063 (0.756–1.493) | 0.727 | |
| (NACT+CCRT versus CCRT) | 0.652 (0.509–0.833) | 0.001 | |
| (CCRT+ACT versus CCRT) | 0.860 (0.540–1.369) | 0.525 | |
| DMFS | |||
| Gender (Male versus Female) | 0.747 (0.563–0.992) | 0.044 | |
| Cigarette consumption (Yes versus No) | 1.331 (1.087–1.628) | 0.006 | |
| LDH (⩾245 versus <245U/l) | 1.476 (1.146–1.900) | 0.003 | |
| ALB (⩾40 versus<40 g/l) | 0.708 (0.539–0.929) | 0.013 | |
| Treatment modality | <0.001 | ||
| (IMRT alone versus CCRT) | 1.588 (0.933–2.703) | 0.088 | |
| (NACT+IMRT alone versus CCRT) | 1.095 (0.776–1.545) | 0.606 | |
| (NACT+CCRT versus CCRT) | 0.677 (0.528–0.870) | 0.002 | |
| (CCRT+ACT versus CCRT) | 0.947 (0.603–1.487) | 0.813 | |
| LRRFS | |||
| T classification (T4 versus T3) | 1.581 (1.211–2.063) | <0.001 | |
High-risk cluster: mixed type NPC (T3–4N2–3) with high cf EBV DNA load (⩾4000 copies/ml).
ACT, adjuvant chemotherapy; ALB, albumin; CRP, C-reactive protein; CCRT, concurrent chemoradiotherapy; CI, confidence intervals; DMFS, distant metastasis-free survival; HR, hazard ratio; IMRT, intensity modulated radiation therapy; LDH, lactate dehydrogenase; LRRFS, locoregional relapse-free survival; NACT, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival.